NeuroPace, Inc., a medical device company focused on improving the lives of individuals with epilepsy, has announced that an abstract from its Post-approval Study of the RNS System will be presented ...
MOUNTAIN VIEW, Calif., Dec. 01, 2023 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (Nasdaq: NPCE), a commercial-stage medical device company focused on transforming the lives of people living with epilepsy, ...
Zacks Investment Research on MSN
Here's why you should retain NeuroPace stock in your portfolio for now
NeuroPace, Inc. NPCE is well-positioned for solid growth, driven by strong RNS adoption, expanding referral networks and ...
MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--NeuroPace, Inc. today announced that the company has received Breakthrough Device Designation status from the U.S. Food and Drug Administration (FDA) for the ...
In November 2013, the RNS System (responsive neurostimulation; NeuroPace, Inc.) was approved by the US Food and Drug Administration (FDA) for the treatment of focal onset refractory epilepsy. Dileep ...
MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--NeuroPace, Inc., a Silicon Valley-based medical technology company, presented long-term clinical results demonstrating that the RNS ® System for refractory ...
NeuroPace, Inc. NPCE is building a procedure-driven growth story around its RNS System, a brain-responsive implant designed to reduce seizures in adults with drug-resistant focal epilepsy. The company ...
NeuroPace, Inc. today announced that results from its pivotal trial demonstrated the RNS® System, a novel investigational device that utilizes responsive brain neurostimulation, significantly reduced ...
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results